Evidence map›Paper›PMID 35974294›Full record

Trial reportNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2022

Expanding Indications for a Ketogenic Diet as an Adjuvant Therapy in Adult Refractory Status Epilepticus: an Exploratory Study Using Moderation Analysis.

Seungyon Koh, Tae-Joon Kim, Han-Bit Shin, Han Ki Kim, Bumhee Park, So Young Moon, Byung Gon Kim, Kyoon Huh, Jun Young Choi

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Seungyon KohDepartment of Neurology, Ajou University School of Medicine, 164, World cup-ro, Yeongtong-gu, Suwon, Gyeonggi-do, Republic of Korea.
Tae-Joon KimDepartment of Neurology, Ajou University School of Medicine, 164, World cup-ro, Yeongtong-gu, Suwon, Gyeonggi-do, Republic of Korea.
Han-Bit ShinOffice of Biostatics, Ajou Research Institute for Innovation Medicine, Ajou University Medical Center, Suwon, Republic of Korea.
Han Ki KimDepartment of Brain Science, Ajou University School of Medicine, Suwon, Republic of Korea.
Bumhee ParkOffice of Biostatics, Ajou Research Institute for Innovation Medicine, Ajou University Medical Center, Suwon, Republic of Korea.
So Young MoonDepartment of Neurology, Ajou University School of Medicine, 164, World cup-ro, Yeongtong-gu, Suwon, Gyeonggi-do, Republic of Korea.
Byung Gon KimDepartment of Neurology, Ajou University School of Medicine, 164, World cup-ro, Yeongtong-gu, Suwon, Gyeonggi-do, Republic of Korea.
Kyoon HuhDepartment of Neurology, Ajou University School of Medicine, 164, World cup-ro, Yeongtong-gu, Suwon, Gyeonggi-do, Republic of Korea.
Jun Young ChoiDepartment of Neurology, Ajou University School of Medicine, 164, World cup-ro, Yeongtong-gu, Suwon, Gyeonggi-do, Republic of Korea. jychoi@aumc.ac.kr.ORCID 0000-0002-6031-3549
Ajou University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Refractory status epilepticus (RSE) requires multimodal treatment approaches to achieve rapid seizure cessation and neuroprotection. A ketogenic diet (KD) has demonstrated efficacy as a nutritional therapeutic option for adult RSE. However, the group of adult RSE patients who would benefit from adopting a KD needs to be determined to appropriately select the patients indicated for a KD. Therefore, we conducted a nonrandomized retrospective cohort study to explore the therapeutic efficacy of a KD by investigating the moderation effect of a KD on the association between the clinical characteristics of RSE patients and their functional outcomes. This study investigated 140 RSE patients, including 32 patients treated with a KD; among these patients, 28 (81%) achieved seizure cessation. We found that KD moderated the reduction in the modified Rankin scale (mRS) score at discharge among patients who were older, had higher seizure severity scores, were under continuous intravenous anesthetic therapy (CIVAD), and had super-RSE. Age and seizure severity scores, but not CIVAD or super-RSE, were associated with a KD-moderated change in mRS score at 3 months. Thus, we consider that our study provides evidence of a neuroprotective effect of KD in the most severe RSE patients with very few remaining therapeutic options, but future randomized controlled trials in these subgroups of KD patients are necessary.

Indexed as

Diet, KetogenicNeuroprotective AgentsStatus EpilepticusAdultAnesthetics, IntravenousAnticonvulsantsCombined Modality TherapyHumansRetrospective StudiesSeizuresAnesthetics, IntravenousAnticonvulsantsNeuroprotective AgentsKetogenic dietModeration analysisNeuroprotectionNutritional therapyRefractory status epilepticus

Identifiers

PMID35974294
PMCPMC9606186
OpenAlexW4292004198

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.